Triple Negative Breast Cancer: Study of Molecular and Genetic Factors

Overview

Breast cancer triples negatives (TN; 15 % of the cases) are characterized by a high histoprognostic grade, a strong proliferation, a strong metastatic power, and a worse prognosis than the other forms of breast cancer. It is however a heterogenous group for histological and molecular level, but also for evolution. Most of the TN is part of the basal breast cancer subcategory. Until now, the medical treatment is based on chemotherapy. Breast cancers by constitutional mutation of BRCA1 / BRCA2 (5 % of breast cancers) are mostly of basal type and their prognostic seems better that what could be expected from high grade tumours and without hormonal receptors. They would be much more frequent in the TN group. However, at this day, no prospective study was led to estimate this incidence, or to study the intervention of other genes of predisposition, as well to analyse the links between this phenotype and their consequences at the germinal or somatic level, in terms of associated molecular changes and prognosis. The purpose of this study is, on a prospective study, to lead a joined analysis at the germinal level, in search of mutations of the main genes of breast cancer predisposition (BRCA1/2, PALB2, PTEN, PALB2), and at the tumour level (tissue micro-array and transcriptome), by correlating these results to the main clinical parameters. The 5 years relapse-free survival will also be estimated.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2014

Interventions

  • Genetic: BRCA1 BRCA2 PTEN PALB2 mutation
    • detection of BRCA1 BRCA2 PTEN PALB2 mutation

Arms, Groups and Cohorts

  • Experimental: Triple negative breast cancer
    • Triple negative breast cancer

Clinical Trial Outcome Measures

Primary Measures

  • incidence of BRCA1/2, PALB2, PTEN, PALB2 mutations
    • Time Frame: up to 1 month
    • 1) Determine the incidence of the BRCA1/2, PALB2, PTEN, PALB2 mutations in patients having at diagnosis a non metastatic triple negative breast cancer

Secondary Measures

  • molecular profiles
    • Time Frame: up to 1 month
    • 2) Determine by tissue micro- array and transcriptome the molecular profiles and their correlation with the presence of a mutation
  • years relapse-free survival
    • Time Frame: at 5 years
    • 3) Determine the 5 years relapse-free survival in presence or not of a mutation, and according to the molecular profile of expression.

Participating in This Clinical Trial

Inclusion Criteria

  • women > 18 – non metastatic breast cancer – triple negative – 5 years follow-up – signed informed consent Exclusion Criteria:

  • other cancer (except in situ) – metastases at diagnosis – impossibility of follow-up

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Institut Paoli-Calmettes
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jean-Marc EXTRA, MD, Principal Investigator, Institut Paoli-Calmettes

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.